Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION

v3.10.0.1
SEGMENT INFORMATION
9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
SEGMENT INFORMATION

NOTE 17 – SEGMENT INFORMATION

 

For the three and nine months ended September 30, 2018, the Company operated in three reportable business segments - (1) the real property operating segment, (2) the medical related consulting services segment, and (3) the performing development services for hospitals and other customers and sales of developed products to hospitals and other customers segment. For the three and nine months ended September 30, 2017, the Company operated in two reportable business segments - (1) the real property operating segment, and (2) the medical related consulting services segment. The Company’s reportable segments are strategic business units that offer different services and products. They are managed separately based on the fundamental differences in their operations. Information with respect to these reportable business segments for the three and nine months ended September 30, 2018 and 2017 was as follows:

 

    Three Months
Ended
September 30, 2018
    Three Months
Ended
September 30, 2017
    Nine Months
Ended
September 30, 2018
    Nine Months
Ended
September 30, 2017
 
Revenues                                
  Real property operating   $ 272,444     $ 315,284     $ 847,939     $ 537,538  
  Medical related consulting services – related parties     71,398       2,166       213,394       220,949  
  Development services and sales of developed products     69,661             156,176        
      413,503       317,450       1,217,509       758,487  
Depreciation and amortization                                
  Real property operating     32,624       20,568       97,873       53,511  
  Medical related consulting services     4,706       3,754       12,703       4,967  
  Development services and sales of developed products     98,298             273,027        
      135,628       24,322       383,603       58,478  
Interest expense                                
  Real property operating     25,205       52,932       287,123       94,932  
  Medical related consulting services                        
  Development services and sales of developed products                        
      25,205       52,932       287,123       94,932  
Net income (loss)                                
  Real property operating     542       (119,782 )     (231,541 )     (121,016 )
  Medical related consulting services     (75,484 )     (116,230 )     (232,502 )     (278,019 )
  Development services and sales of developed products     (146,451 )           (443,479 )      
  Other (a)     (2,181,858 )     (474,717 )     (4,390,513 )     (1,291,535 )
    $ (2,403,251 )   $ (710,729 )   $ (5,298,035 )   $ (1,690,570 )

 

Identifiable long-lived tangible assets at September 30, 2018 and December 31, 2017   September 30, 2018     December 31,
2017
 
Real property operating   $ 7,940,069     $ 7,645,371  
Medical related consulting services     8,640       20,558  
Development services and sales of developed products     243,729       5,857  
    $ 8,192,438     $ 7,671,786  

 

Identifiable long-lived tangible assets at September 30, 2018 and December 31, 2017   September 30, 2018     December 31,
2017
 
United States   $ 7,940,730     $ 7,646,270  
China     251,708       25,516  
    $ 8,192,438     $ 7,671,786  

 

  (a) The Company does not allocate any general and administrative expense of its being a public company activities to its reportable segments as these activities are managed at a corporate level.